Why Derma Sciences Is Poised to Pull Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, wound care products company Derma Sciences has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Derma Sciences and see what CAPS investors are saying about the stock right now.
Derma Sciencesfacts
Headquarters (founded) | Princeton, N.J. (since 1984) |
Market Cap | $162.3 million |
Industry | Health care supplies |
Trailing-12-Month Revenue | $69.1 million |
Management | Chairman/CEO Edward Quilty |
Return on Equity (average, past 3 years) | (11.1%) |
Cash/Debt | $15.6 million / $0 |
Competitors | ConvaTec |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 55% of the 22 members who have rated Derma Sciences believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the Derma Sciences bear case for our community:
I've never been a believer in Derma so I'll fling myself onto this rising knife. There's no consistent upward trend in quarterly revenues and the company seems to be dragging their heels on a phase III trial of DSC127 . Could that be because the FDA wants an active comparator instead of placebo and the company knows they won't get stat sig in ulcer healing with that approach? Meanwhile, the dilution continues. As I've said before, I don't grudge Derma [$100M] in enterprise value. Above that I start getting skeptical.
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Derma Sciences Is Poised to Pull Back originally appeared on Fool.com.
Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Covidien Ltd. and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
